首页> 外文期刊>Blood: The Journal of the American Society of Hematology >Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.
【24h】

Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.

机译:使用全基因组测序对弥漫性大B细胞淋巴瘤进行突变和结构分析。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Diffuse large B-cell lymphoma (DLBCL) is a genetically heterogeneous cancer composed of at least 2 molecular subtypes that differ in gene expression and distribution of mutations. Recently, application of genome/exome sequencing and RNA-seq to DLBCL has revealed numerous genes that are recurrent targets of somatic point mutation in this disease. Here we provide a whole-genome-sequencing-based perspective of DLBCL mutational complexity by characterizing 40 de novo DLBCL cases and 13 DLBCL cell lines and combining these data with DNA copy number analysis and RNA-seq from an extended cohort of 96 cases. Our analysis identified widespread genomic rearrangements including evidence for chromothripsis as well as the presence of known and novel fusion transcripts. We uncovered new gene targets of recurrent somatic point mutations and genes that are targeted by focal somatic deletions in this disease. We highlight the recurrence of germinal center B-cell-restricted mutations affecting genes that encode the S1P receptor and 2 small GTPases (GNA13 and GNAI2) that together converge on regulation of B-cell homing. We further analyzed our data to approximate the relative temporal order in which some recurrent mutations were acquired and demonstrate that ongoing acquisition of mutations and intratumoral clonal heterogeneity are common features of DLBCL. This study further improves our understanding of the processes and pathways involved in lymphomagenesis, and some of the pathways mutated here may indicate new avenues for therapeutic intervention.
机译:弥漫性大B细胞淋巴瘤(DLBCL)是一种遗传异质性癌症,由至少两种在基因表达和突变分布上不同的分子亚型组成。最近,将基因组/外显子组测序和RNA-seq应用于DLBCL已揭示了许多基因,这些基因是该病中体细胞点突变的复发靶标。在这里,我们通过表征40个从头开始的DLBCL病例和13个DLBCL细胞系并将这些数据与DNA拷贝数分析和来自96个病例组的RNA-seq相结合,提供了基于全基因组测序的DLBCL突变复杂性的观点。我们的分析确定了广泛的基因组重排,包括色杆菌病的证据以及已知和新颖的融合转录本的存在。我们发现了复发性体细胞点突变的新基因靶标和该病中局灶性体细胞缺失的基因。我们强调了生发中心B细胞限制性突变的复发,这些突变影响编码S1P受体和2个小GTP酶(GNA13和GNAI2)的基因,这些基因共同收敛于对B细胞归巢的调节。我们进一步分析了我们的数据,以近似得出一些复发突变的相对时间顺序,并证明正在进行的突变捕获和肿瘤内克隆异质性是DLBCL的共同特征。这项研究进一步提高了我们对涉及淋巴瘤发生的过程和途径的理解,并且此处突变的某些途径可能为治疗干预提供了新途径。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号